208 related articles for article (PubMed ID: 26861948)
1. High levels of AGE-LDL, and of IgG antibodies reacting with MDA-lysine epitopes expressed by oxLDL and MDA-LDL in circulating immune complexes predict macroalbuminuria in patients with type 2 diabetes.
Lopes-Virella MF; Hunt KJ; Baker NL; Virella G;
J Diabetes Complications; 2016; 30(4):693-9. PubMed ID: 26861948
[TBL] [Abstract][Full Text] [Related]
2. The levels of MDA-LDL in circulating immune complexes predict myocardial infarction in the VADT study.
Lopes-Virella MF; Hunt KJ; Baker NL; Virella G; Moritz T;
Atherosclerosis; 2012 Oct; 224(2):526-31. PubMed ID: 22963984
[TBL] [Abstract][Full Text] [Related]
3. High levels of oxidized LDL in circulating immune complexes are associated with increased odds of developing abnormal albuminuria in Type 1 diabetes.
Lopes-Virella MF; Carter RE; Baker NL; Lachin J; Virella G;
Nephrol Dial Transplant; 2012 Apr; 27(4):1416-23. PubMed ID: 21856760
[TBL] [Abstract][Full Text] [Related]
4. Oxidized LDL-anti-oxidized LDL immune complexes and diabetic nephropathy.
Atchley DH; Lopes-Virella MF; Zheng D; Kenny D; Virella G
Diabetologia; 2002 Nov; 45(11):1562-71. PubMed ID: 12436340
[TBL] [Abstract][Full Text] [Related]
5. Levels of oxidized LDL and advanced glycation end products-modified LDL in circulating immune complexes are strongly associated with increased levels of carotid intima-media thickness and its progression in type 1 diabetes.
Lopes-Virella MF; Hunt KJ; Baker NL; Lachin J; Nathan DM; Virella G;
Diabetes; 2011 Feb; 60(2):582-9. PubMed ID: 20980456
[TBL] [Abstract][Full Text] [Related]
6. Soluble LDL-immune complexes in type 2 diabetes and vascular disease.
Turk Z; Sesto M; Skodlar J; Ferencak G; Turk N; Stavljenić-Rukavina A
Horm Metab Res; 2002 Apr; 34(4):196-201. PubMed ID: 11987029
[TBL] [Abstract][Full Text] [Related]
7. Malondialdehyde-modified LDL-related variables are associated with diabetic kidney disease in type 2 diabetes.
Furukawa S; Suzuki H; Fujihara K; Kobayashi K; Iwasaki H; Sugano Y; Yatoh S; Sekiya M; Yahagi N; Shimano H
Diabetes Res Clin Pract; 2018 Jul; 141():237-243. PubMed ID: 29775676
[TBL] [Abstract][Full Text] [Related]
8. Definition of the immunogenic forms of modified human LDL recognized by human autoantibodies and by rabbit hyperimmune antibodies.
Virella G; Thorpe SR; Alderson NL; Derrick MB; Chassereau C; Rhett JM; Lopes-Virella MF
J Lipid Res; 2004 Oct; 45(10):1859-67. PubMed ID: 15258197
[TBL] [Abstract][Full Text] [Related]
9. Oxidized LDL and AGE-LDL in circulating immune complexes strongly predict progression of carotid artery IMT in type 1 diabetes.
Hunt KJ; Baker N; Cleary P; Backlund JY; Lyons T; Jenkins A; Virella G; Lopes-Virella MF;
Atherosclerosis; 2013 Dec; 231(2):315-22. PubMed ID: 24267245
[TBL] [Abstract][Full Text] [Related]
10. The immunogenicity of modified lipoproteins.
Lopes-Virella MF; Thorpe SR; Derrick MB; Chassereau C; Virella G
Ann N Y Acad Sci; 2005 Jun; 1043():367-78. PubMed ID: 16037258
[TBL] [Abstract][Full Text] [Related]
11. High plasma immunoglobulin (Ig) A and low IgG antibody titers to oxidized low-density lipoprotein are associated with markers of glucose metabolism.
Sämpi M; Veneskoski M; Ukkola O; Kesäniemi YA; Hörkkö S
J Clin Endocrinol Metab; 2010 May; 95(5):2467-75. PubMed ID: 20332251
[TBL] [Abstract][Full Text] [Related]
12. Distribution of IgM and IgG antibodies to oxidized LDL in immune complexes isolated from patients with type 1 diabetes and its relationship with nephropathy.
Virella G; Carter RE; Saad A; Crosswell EG; Game BA; ; Lopes-Virella MF
Clin Immunol; 2008 Jun; 127(3):394-400. PubMed ID: 18533284
[TBL] [Abstract][Full Text] [Related]
13. Antibodies to oxidized LDL and LDL-containing immune complexes as risk factors for coronary artery disease in diabetes mellitus.
Lopes-Virella MF; Virella G; Orchard TJ; Koskinen S; Evans RW; Becker DJ; Forrest KY
Clin Immunol; 1999 Feb; 90(2):165-72. PubMed ID: 10080827
[TBL] [Abstract][Full Text] [Related]
14. Development of capture assays for different modifications of human low-density lipoprotein.
Virella G; Derrick MB; Pate V; Chassereau C; Thorpe SR; Lopes-Virella MF
Clin Diagn Lab Immunol; 2005 Jan; 12(1):68-75. PubMed ID: 15642987
[TBL] [Abstract][Full Text] [Related]
15. Pathogenic role of modified LDL antibodies and immune complexes in atherosclerosis.
Lopes-Virella MF; Virella G
J Atheroscler Thromb; 2013; 20(10):743-54. PubMed ID: 23965492
[TBL] [Abstract][Full Text] [Related]
16. Risk Prediction for Early CKD in Type 2 Diabetes.
Dunkler D; Gao P; Lee SF; Heinze G; Clase CM; Tobe S; Teo KK; Gerstein H; Mann JF; Oberbauer R;
Clin J Am Soc Nephrol; 2015 Aug; 10(8):1371-9. PubMed ID: 26175542
[TBL] [Abstract][Full Text] [Related]
17. Autoantibodies and immune complexes to oxidation-specific epitopes and progression of aortic stenosis: Results from the ASTRONOMER trial.
Capoulade R; Chan KL; Mathieu P; Bossé Y; Dumesnil JG; Tam JW; Teo KK; Yang X; Witztum JL; Arsenault BJ; Després JP; Pibarot P; Tsimikas S
Atherosclerosis; 2017 May; 260():1-7. PubMed ID: 28319871
[TBL] [Abstract][Full Text] [Related]
18. The Pathogenic Role of the Adaptive Immune Response to Modified LDL in Diabetes.
Virella G; Lopes-Virella MF
Front Endocrinol (Lausanne); 2012; 3():76. PubMed ID: 22715334
[TBL] [Abstract][Full Text] [Related]
19. Early urinary markers of diabetic kidney disease: a nested case-control study from the Diabetes Control and Complications Trial (DCCT).
Kern EF; Erhard P; Sun W; Genuth S; Weiss MF
Am J Kidney Dis; 2010 May; 55(5):824-34. PubMed ID: 20138413
[TBL] [Abstract][Full Text] [Related]
20. Reduced levels of anti-MDA LDL antibodies in patients with carbohydrate metabolism disorders.
Garrido-Sánchez L; García-Pinilla JM; Jiménez-Navarro M; Fernández-Pastora J; Alonso-Briales JH; Hernández-Garcia JM; De-Teresa-Galván E; Tinahones FJ
Clin Lab; 2011; 57(11-12):901-7. PubMed ID: 22239020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
